PART 01: EXECUTIVE SUMMARY PART 02: SCOPE OF THE REPORT 2.1 Preface 2.2 Preface 2.3 Currency conversion rates for US$ PART 03: MARKET LANDSCAPE Market ecosystem Market characteristics Market segmentation analysis PART 04: MARKET SIZING Market definition Market sizing 2018 Market size and forecast 2018-2023 PART 05: FIVE FORCES ANALYSIS Bargaining power of buyers Bargaining power of suppliers Threat of new entrants Threat of substitutes Threat of rivalry Market condition PART 06: MARKET SEGMENTATION BY PRODUCT Market segmentation by product Comparison by product Combination therapy - Market size and forecast 2018-2023 Monotherapy - Market size and forecast 2018-2023 Market opportunity by product PART 07: CUSTOMER LANDSCAPE PART 08: GEOGRAPHIC LANDSCAPE Geographic segmentation Geographic comparison North America - Market size and forecast 2018-2023 Europe - Market size and forecast 2018-2023 Asia - Market size and forecast 2018-2023 ROW - Market size and forecast 2018-2023 Key leading countries Market opportunity PART 09: DECISION FRAMEWORK PART 10: DRIVERS AND CHALLENGES Market drivers Market challenges PART 11: MARKET TRENDS Increase of patient assistance programs Strategic alliances Development of novel formulations PART 12: VENDOR LANDSCAPE Overview Landscape disruption PART 13: VENDOR ANALYSIS Vendors covered Vendor classification Market positioning of vendors AbbVie Inc. F. Hoffmann-La Roche Ltd. PART 14: APPENDIX Research methodology List of abbreviations Definition of market positioning of vendors PART 15: EXPLORE TECHNAVIO   Exhibit 01: Product overview Exhibit 02: Global pharmaceuticals market Exhibit 03: Segments of global pharmaceuticals market Exhibit 04: Market characteristics Exhibit 05: Market segments Exhibit 06: Market definition - Inclusions and exclusions checklist Exhibit 07: Market size 2018 Exhibit 08: Global market: Size and forecast 2018-2023 ($ millions) Exhibit 09: Global market: Year-over-year growth 2019-2023 (%) Exhibit 10: Five forces analysis 2018 Exhibit 11: Five forces analysis 2023 Exhibit 12: Bargaining power of buyers Exhibit 13: Bargaining power of suppliers Exhibit 14: Threat of new entrants Exhibit 15: Threat of substitutes Exhibit 16: Threat of rivalry Exhibit 17: Market condition - Five forces 2018 Exhibit 18: Product - Market share 2018-2023 (%) Exhibit 19: Comparison by product Exhibit 20: Combination therapy - Market size and forecast 2018-2023 ($ millions) Exhibit 21: Some of the approved combination therapies Exhibit 22: Combination therapy - Year-over-year growth 2019-2023 (%) Exhibit 23: Monotherapy - Market size and forecast 2018-2023 ($ millions) Exhibit 24: Monotherapy - Year-over-year growth 2019-2023 (%) Exhibit 25: Market opportunity by product Exhibit 26: Customer landscape Exhibit 27: Market share by geography 2018-2023 (%) Exhibit 28: Geographic comparison Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions) Exhibit 30: Prevalence, incidence, and mortality in the US are tabulated as follows. Exhibit 31: North America - Year-over-year growth 2019-2023 (%) Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions) Exhibit 33: Europe - Year-over-year growth 2019-2023 (%) Exhibit 34: Asia - Market size and forecast 2018-2023 ($ millions) Exhibit 35: Asia - Year-over-year growth 2019-2023 (%) Exhibit 36: ROW - Market size and forecast 2018-2023 ($ millions) Exhibit 37: ROW - Year-over-year growth 2019-2023 (%) Exhibit 38: Key leading countries Exhibit 39: Market opportunity Exhibit 40: Impact of drivers and challenges Exhibit 41: Vendor landscape Exhibit 42: Landscape disruption Exhibit 43: Vendors covered Exhibit 44: Vendor classification Exhibit 45: Market positioning of vendors Exhibit 46: AbbVie Inc. - Vendor overview Exhibit 47: AbbVie Inc. - Business segments Exhibit 48: AbbVie Inc. - Organizational developments Exhibit 49: AbbVie Inc. - Geographic focus Exhibit 50: AbbVie Inc. - Key offerings Exhibit 51: AbbVie Inc. - Key customers Exhibit 52: F. Hoffmann-La Roche Ltd. - Vendor overview Exhibit 53: F. Hoffmann-La Roche Ltd. - Product segments Exhibit 54: F. Hoffmann-La Roche Ltd. - Organizational developments Exhibit 55: F. Hoffmann-La Roche Ltd. - Geographic focus Exhibit 56: F. Hoffmann-La Roche Ltd. - Segment focus Exhibit 57: F. Hoffmann-La Roche Ltd. - Key offerings Exhibit 58: F. Hoffmann-La Roche Ltd. - Key customers Exhibit 59: Validation techniques employed for market sizing Exhibit 60: Definition of market positioning of vendors

AbbVie Inc. and F. Hoffmann-La Roche Ltd.